Press Releases

October 11, 2016 New TissueCypher® Validation Study identifies high risk Barrett’s Esophagus patients who are 46x more likely to have cancer at time of biopsy

Study indicates that TissueCypher® may detect a field effect associated with high grade dysplasia and cancer, which can be challenging to recognize with standard endoscopic and histologic surveillance BETHLEHEM, PA. – A recent study publish... Read more

September 22, 2017 Cernostics Announces Leadership Team Expansion

– New Commercial Leader Positions Company for Continued Success and Growth – BETHLEHEM and PITTSBURGH, Penn. – September 12, 2017 – Cernostics, a privately-held diagnostics company focused on delivering next-generation cancer dia... Read more

March 21, 2018 Cernostics Raises $2.5 Million in Series A1 Financing, Led by Illumina Ventures

– TissueCypher® Barrett’s Esophagus Assay is First Precision Medicine Platform for Prevention of Esophageal Cancer – PITTSBURGH, Penn., March 21 2018 — Cernostics, a privately-held company focused on delivering next-generation cance... Read more

November 20, 2018 Cernostics Secures Additional Patents for Proprietary Barrett’s Esophagus Clinical Diagnostics

– US and EU patents for TissueCypher® cover methods for detecting risk of progression to esophageal cancer in Barrett’s esophagus patients – PITTSBURGH, Penn., November 20, 2018 — Cernostics, developer of next-generation cancer dia... Read more

May 8, 2019 Blinded Independent Validation Study of Tissue Systems Pathology Test in Determining Risk of Progression to Esophageal Cancer in Patients with Barrett’s Esophagus to be Presented at DDW 2019

PITTSBURGH, May 08, 2019 (GLOBE NEWSWIRE) — Cernostics, developer of next-generation cancer diagnostics and prognostics today announced that the results of an independent study validating the use of its TissueCypher Barrett’s Esophagus Assay ... Read more

July 1, 2019 Cernostics Announces Formation of Distinguished Medical Advisory Board Including Top Specialists in All Facets of Esophageal Disease

PITTSBURGH, Penn., July 1, 2019 — Cernostics, developer of next-generation cancer diagnostics and prognostics, today announced the formation of a distinguished medical advisory board (MAB) including key opinion leaders and world-renowned exp... Read more

October 22, 2019 TissueCypher® Further Validated to Accurately Risk Stratify Barrett’s Esophagus Patients with Non-Dysplastic or Low-Grade Dysplasia Diagnoses: Findings Shared at Two Major GI Conferences

Data presented at ACG, UEGW illustrates the 4th independent validation of TissueCypher performance for risk stratifying non-dysplastic Barrett’s esophagus (NDBE) patients; expands indication for testing low-grade dysplasia (LGD) PITTSBURGH, ... Read more

News